Center-Authored Papers

Filters: Author is Barlogie, Bart  [Clear All Filters]
Journal Article
Usmani S, Sexton R, Crowley J, Barlogie B.  2011.  Autologous stem cell transplantation as a care option in Waldenström's macroglobulinemia.. Clinical lymphoma, myeloma & leukemia. 11(1):139-42. Abstract
Dhodapkar MV, Sexton R, Waheed S, Usmani S, Papanikolaou X, Nair B, Petty N, Shaughnessy JD, Hoering A, Crowley J et al..  2013.  Clinical, genomic and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120).. Blood. Abstract
Hoering A, Crowley J, Shaughnessy JD, Hollmig K, Alsayed Y, Szymonifka J, Waheed S, Nair B, van Rhee F, Anaissie E et al..  2009.  Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols.. Blood. 114(7):1299-305. Abstract
Othus M, Barlogie B, Leblanc ML, Crowley JJ.  2012.  Cure Models as a Useful Statistical Tool for Analyzing Survival.. Clinical cancer research : an official journal of the American Association for Cancer Research. 18(14):3731-3736. Abstract
Zhou Y, Nair B, Shaughnessy JD, Cartron M-A, Haessler J, Anaissie E, van Rhee F, Crowley J, Barlogie B.  2009.  Cytogenetic abnormalities in multiple myeloma: poor prognosis linked to concomitant detection in random and focal lesion bone marrow samples and associated with high-risk gene expression profile.. British journal of haematology. 145(5):637-41. Abstract
Bartel TB, Haessler J, Brown TLY, Shaughnessy JD, van Rhee F, Anaissie E, Alpe T, Angtuaco E, Walker R, Epstein J et al..  2009.  F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma.. Blood. 114(10):2068-76. Abstract
Khan R, Dhodapkar M, Rosenthal A, Heuck C, Papanikolaou X, Qu P, van Rhee F, Zangari M, Jethava Y, Epstein J et al..  2015.  Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120).. Haematologica. Abstract
Morel P, Duhamel A, Gobbi P, Dimopoulos MA, Dhodapkar MV, McCoy J, Crowley J, Ocio EM, Garcia-Sanz R, Treon SP et al..  2009.  International prognostic scoring system for Waldenstrom macroglobulinemia.. Blood. 113(18):4163-70. Abstract
Waheed S, Shaughnessy JD, van Rhee F, Alsayed Y, Nair B, Anaissie E, Szymonifka J, Hoering A, Crowley J, Barlogie B.  2011.  International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocols.. Cancer. 117(5):1001-9. Abstract
Zonder JA, Crowley J, Hussein MA, Bolejack V, Moore DF, Whittenberger BF, Abidi MH, Durie BGM, Barlogie B.  2010.  Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232).. Blood. 116(26):5838-41. Abstract
Barlogie B, Attal M, Crowley J, van Rhee F, Szymonifka J, Moreau P, Durie BGM, Harousseau J-L.  2010.  Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(7):1209-14. Abstract
Dhodapkar MV, Hoering A, Gertz MA, Rivkin S, Szymonifka J, Crowley J, Barlogie B.  2009.  Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003.. Blood. 113(4):793-6. Abstract
Papanikolaou X, Szymonifka J, Rosenthal A, Heuck CJ, Mitchell A, Johann D, Keller J, Waheed S, Usmani SZ, van Rhee F et al..  2013.  Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myeloma.. Haematologica. 98(7):1147-53. Abstract
Shaughnessy JD, Qu P, Usmani S, Heuck CJ, Zhang Q, Zhou Y, Tian E, Hanamura I, van Rhee F, Anaissie E et al..  2011.  Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with total therapy 3.. Blood. 118(13):3512-3524. Abstract
Hussein MA, Bolejack V, Zonder JA, Durie BGM, Jakubowiak AJ, Crowley J, Barlogie B.  2009.  Phase II study of thalidomide plus dexamethasone induction followed by tandem melphalan-based autotransplantation and thalidomide-plus-prednisone maintenance for untreated multiple myeloma: a southwest oncology group trial (S0204).. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(21):3510-7. Abstract
Barlogie B, Bolejack V, Schell M, Crowley J.  2011.  Prognostic factor analyses of myeloma survival with intergroup trial S9321 (INT 0141): examining whether different variables govern different time segments of survival.. Annals of hematology. 90(4):423-8. Abstract
Usmani SZ, Mitchell A, Waheed S, Crowley J, Hoering A, Petty N, Brown T, Bartel T, Anaissie E, van Rhee F et al..  2013.  Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with Total Therapy 3.. Blood. Abstract
Barlogie B, Anaissie E, van Rhee F, Shaughnessy JD, Szymonifka J, Hoering A, Petty N, Crowley J.  2010.  Reiterative survival analyses of total therapy 2 for multiple myeloma elucidate follow-up time dependency of prognostic variables and treatment arms.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(18):3023-7. Abstract
Stein CK, Qu P, Epstein J, Buros A, Rosenthal A, Crowley J, Morgan G, Barlogie B.  2015.  Removing batch effects from purified plasma cell gene expression microarrays with modified ComBat.. BMC bioinformatics. 16(1):63. Abstract
Usmani SZ, Sawyer J, Rosenthal A, Cottler-Fox M, Epstein J, Yaccoby S, Sexton R, Hoering A, Singh Z, Heuck CJ et al..  2013.  Risk Factors for MDS and Acute Leukemia Following Total Therapy 2 and 3 for Multiple Myeloma.. Blood. Abstract
Nair B, van Rhee F, Shaughnessy JD, Anaissie E, Szymonifka J, Hoering A, Alsayed Y, Waheed S, Crowley J, Barlogie B.  2010.  Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance.. Blood. 115(21):4168-73. Abstract
Ludwig H, Bolejack V, Crowley J, Bladé J, Miguel JS, Kyle RA, Rajkumar VS, Shimizu K, Turesson I, Westin J et al..  2010.  Survival and years of life lost in different age cohorts of patients with multiple myeloma.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(9):1599-605. Abstract
van Rhee F, Szymonifka J, Anaissie E, Nair B, Waheed S, Alsayed Y, Petty N, Shaughnessy JD, Hoering A, Crowley J et al..  2010.  Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy.. Blood. 116(8):1220-7. Abstract
Shaughnessy JD, Zhou Y, Haessler J, van Rhee F, Anaissie E, Nair B, Waheed S, Alsayed Y, Epstein J, Crowley J et al..  2009.  TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3.. British journal of haematology. 147(3):347-51. Abstract
Dimopoulos M, Kastritis E, Owen RG, Kyle RA, Landgren O, Morra E, Leleu X, García-Sanz R, Munshi N, Anderson KC et al..  2014.  Treatment recommendations for patients with Waldenström's Macroglobulinemia (WM) and related disorders: consensus from the Seventh International Workshop on WM.. Blood. Abstract